Article
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Asian Pacific journal of cancer prevention : APJCP - 1 Dec 2020
Iqbal Zafar, Absar Muhammad, Mahmood Amer, Aleem Aamer, Iqbal Mudassar, Jameel Abid, Akhtar Tanveer, Karim Sajjad, Rasool Mahmood, Mirza Zeenat, Khalid Muhammad, Akram Afia Muhammad, Sabar Muhammad Farooq, Khalid Ahmad M, Aljarrah Khalid, Iqbal Janhangir, Khalid Muhammad, Shah Ijaz H, Alanazi Nawaf
Abstract excerpt
OBJECTIVE: BCR-ABL fusion oncogene is the hallmark of chronic myeloid leukemia (CML), causing genomic instability which leads to accumulation of mutations in BCR-ABL as well as other genes. BCR-ABL mutations are the cause of tyrosine kinase inhibitors (TKIs) resistance in CML. Recently, compound BCR-ABL mutations have been reported to resist all FDA approved TKIs. Therefore, finding novel compound BCR-ABL...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.